F077 Navigating the Shoals of Cutaneous Lymphoma: Challenges and Controversies
DESCRIPTION
This session will discuss challenges and controversies in CTCL, and provide practical pearls for the general dermatologist. 1. Challenging cases of CTCL that took years for diagnosis, and lessons learned 2. Mimickers of CTCL, and how to utilize tools such as flow cytometry and T-cell gene rearrangement (and pitfalls) 3. Management of CTCL in certain populations, including pediatric, pregnant, and skin of color 4. Does dupilumab cause exacerbation of CTCL? 5. JAK inhibitors and CTCL- friend or foe? We will review the evidence and discuss the potential role for JAK inhibition in treatment of CTCL.
LEARNING OBJECTIVES
Discuss diagnostic challenges in cutaneous T-cell lymphoma (CTCL), including cases that were "missed," as well as conditions that can mimic CTCL. Learn how to utilize tests that can help in challenging cases, as well as potential pitfalls in the interpretation of these tests
Discuss the overlapping spectrum of CD30+ lymphoproliferative disorders (lymphomatoid papulosis, mycosis fungoides, and anaplastic large cell lymphoma)
Examine the current evidence behind the controversial association between biologic therapies and CTCL. Do biologic therapies truly worsen CTCL, or it is "unmasking" of untreated disease?
DIRECTOR
Jina Chung, MD, FAAD
University of Pennsylvania
SPEAKERS
Michi Shinohara, MD, FAAD
University of Washington/Fred Hutch Cancer Center
Jennifer Yu Wang, MD, FAAD
Xiaolong Alan Zhou, MD, MSc, FAAD
DISCLOSURES
Jina Chung, MD, FAAD
No financial relationships exist with ineligible companies.
Michi Shinohara, MD, FAAD
No financial relationships exist with ineligible companies.
Jennifer Yu Wang, MD, FAAD
Enspectra Health – Consultant (1099 relationship)(Fees);
Xiaolong Alan Zhou, MD, MSc, FAAD
Kyowa Kirin – Consultant (1099 relationship)(Fees); Therakos, Inc. – Consultant (1099 relationship)(Fees);